US20140113817A1 - Peptides with antimicrobial activity, drug compositions for the treatment and prophylaxis of animals, compositions for the treatment and prophylaxis of plants, uses of said peptides, and uses of paenibacillus elgil ourofinensis extract - Google Patents

Peptides with antimicrobial activity, drug compositions for the treatment and prophylaxis of animals, compositions for the treatment and prophylaxis of plants, uses of said peptides, and uses of paenibacillus elgil ourofinensis extract Download PDF

Info

Publication number
US20140113817A1
US20140113817A1 US14/111,707 US201114111707A US2014113817A1 US 20140113817 A1 US20140113817 A1 US 20140113817A1 US 201114111707 A US201114111707 A US 201114111707A US 2014113817 A1 US2014113817 A1 US 2014113817A1
Authority
US
United States
Prior art keywords
paenibacillus
treatment
prophylaxis
animals
extract
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/111,707
Other languages
English (en)
Inventor
Carlos Henrique Henrique
Janaina Fernandez De Araújo
Alinne Pereira De Castro
Lucas Carvalho
Octávio Luis Franco
Adriane Kurokawa Silva
Ricardo Enrique Kruger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UNAIO BRASILIENSE DE EDUCACO E CULTURA-UBEC
Ouro Fino Participacoes e Empreendimentos S/A
Uniao Brasiliense de Educacao e Cultura UBEC
Original Assignee
UNAIO BRASILIENSE DE EDUCACO E CULTURA-UBEC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UNAIO BRASILIENSE DE EDUCACO E CULTURA-UBEC filed Critical UNAIO BRASILIENSE DE EDUCACO E CULTURA-UBEC
Publication of US20140113817A1 publication Critical patent/US20140113817A1/en
Assigned to OURO FINO PARTICIPACOES E EMPREENDIMENTOS S/A, UNIAO BRASILIENSE DE EDUCACAO E CULTURA - UBEC reassignment OURO FINO PARTICIPACOES E EMPREENDIMENTOS S/A ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HENRIQUE, Carlos Henrique, CARVALHO, Lucas, DE ARAUJO, JANAINA FERNANDEZ, DE CASTRO, ALINNE PEREIRA, FRANCO, OCTAVIO LUIS, KRUGER, RICARDO HENRIQUE, SILVA, ADRIANE KUROKAWA
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A01N63/02—
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
    • A01N63/10—Animals; Substances produced thereby or obtained therefrom
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
    • A01N63/50—Isolated enzymes; Isolated proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/12—Animal feeding-stuffs obtained by microbiological or biochemical processes by fermentation of natural products, e.g. of vegetable material, animal waste material or biomass
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/142—Amino acids; Derivatives thereof
    • A23K20/147—Polymeric derivatives, e.g. peptides or proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/30—Feeding-stuffs specially adapted for particular animals for swines
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/70—Feeding-stuffs specially adapted for particular animals for birds
    • A23K50/75—Feeding-stuffs specially adapted for particular animals for birds for poultry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K11/02—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention relates to a lipopeptide with antimicrobial activity and growth-promoting activity of organisms, especially plants and animals.
  • the lipopeptides of the invention were identified from extracts of the culture of bacterial isolate of the genus Paenibacillus , more specifically the isolate of Paenibacillus elgii .
  • the invention further relates to the use of the isolate Paenibacillus extract as a growth promoter and in the treatment and prophylaxis of organisms, such as plants and animals.
  • the invention further relates to the use of the peptides of the invention as a growth promoter and in the treatment and prophylaxis of organisms, such as plants and animals.
  • the present invention relates to drug compositions for the treatment and prophylaxis of animals, said composition comprising a therapeutically or prophylactically effective amount of the peptides of the invention in association with a pharmaceutically acceptable carrier or excipient.
  • Antibiotics are the most exploited microbial products in the biotechnology industry.
  • the technology used for the treatment of veterinary infections and in the promotion of animal growth is based on conventional antibiotics.
  • Bacillus subtilis, Escherichia coli and Salmonella enteritidis that cause infections in chickens are resistant to known antimicrobial agents such as tetracycline, nalidixic acid, ampicillin, and others (see Ribeiro, A. R., Kellermann, A., Santos, L. R., Nascimento V. P. 2008.
  • the antimicrobial agents can be natural or synthetic substances which inhibit or kill microorganisms, including bacteria.
  • microorganisms including bacteria.
  • antimicrobial substances which differ in chemical structure and mechanism of action, causing them to be highly specific in the treatment of specific pathogens.
  • the emergence of antimicrobial agents was the great victory of the 20th century in the fields of medicine, veterinary medicine and agriculture, not only for its therapeutic value, but also for its property to promote the growth of plants and animals when used in sub-therapeutic amounts (see “Use of antimicrobials outside human medicine and resultant antimicrobial resistance in humans”, Fact sheet No. 268, January 2002, available on the Web at http://www.who.int/mediacentre/factsheets/fs268/en/).
  • Paenibacillus elgii SD17 as a Biocontrol Agent against Soil-borne Turf Diseases”, Plant Pathol. J. 21(4):328-333, 2005
  • strain SD17 a broad-spectrum antimicrobial activity against diseases caused by microorganisms in grass.
  • Laboratory tests conducted with a granule formulation prepared with the fermentation broth of Paenibacillus elgii SD17 showed efficacy similar to the commercial fungicides, while field tests with the same formulation showed an efficacy lower than the commercial fungicides.
  • the authors considered the granule formulation made with Paenibacillus elgii SD17 an appropriate biocontrol agent.
  • EP 1788074 describes new strains belonging to the genus Paenibacillus and their use, or the culture of these new strains to control plant diseases. These new strains are Paenibacillus sp. BS-0048, Paenibacillus sp. BS-0074, Paenibacillus polymyxa BS-0105 and Paenibacillus sp. BS-0277. This document describes formulations comprising the crude fermentation extract using the new strains and/or compounds produced in these fermentations, such compounds called Fusaricidin A, Fusaricidin B, compound 3 and compound 4 with their chemical formulas defined in claim 3 .
  • the present invention aims at providing Paenibacillus sp extract with antimicrobial activity and/or growth promoter in animals intended for slaughter for human consumption comprising new lipopeptides not described in the prior art with antimicrobial activity. More specifically, the invention provides new peptides derived from the fractions of the fermentation of Paenibacillus extract, preferably Paenibacillus elgii , said novel peptides having antimicrobial activity and promoting the growth of organisms, such as plants and animals. The invention is also related to the use of the extract as a growth promoter and as an antimicrobial agent in the treatment and prophylaxis of animals intended for human consumption.
  • the present invention comprises the process for obtaining the extract comprising at least one of the following compounds shown:
  • process comprises the step of performing the technique of extracting Paenibacillus from the fermentation broth.
  • the present invention comprises extracts of Paenibacillus comprising at least one of the following compounds:
  • a third embodiment of the invention relates to lipopeptides having antimicrobial activity and/or growth promoter, represented below:
  • a fourth embodiment of the invention relates to a drug composition for the prophylaxis and treatment of animals comprising: (i) a therapeutically effective amount of at least one of the following compounds:
  • a fifth embodiment of the invention relates to a drug composition for the prophylaxis and treatment of animals comprising: (i) a therapeutically effective amount of the culture extract of Paenibacillus comprising at least one of the following compounds:
  • a sixth embodiment of the invention relates to a composition for the prophylaxis and treatment of plants comprising: (i) an agriculturally effective amount of at least one of the following compounds:
  • a seventh embodiment of the invention relates to the use of the lipopeptides of the present invention as growth promoters and as antimicrobial agents in the treatment or prophylaxis of animals intended for human consumption.
  • An eighth embodiment of the invention relates to uses of the lipopeptides of the present invention as growth promoters and in the treatment or prophylaxis of the infections caused by phytopathogens in plants.
  • FIG. 1 depicts the FT-MS spectrum of the crude extract produced by P. elgii.
  • FIG. 2 depicts the formula of Permetina A.
  • FIG. 3 depicts the spectrum of CID of the ion m/z of 1101.7 of Permetina A.
  • FIG. 4 depicts the proposed cleavage of Permetina A.
  • FIG. 5 depicts the structural formula of the lipopeptides a) BMY-28160 and b) Permetina A.
  • FIG. 6 depicts the structural formula of a) Permetina A and b) novel Compound 1.
  • FIG. 7 depicts the spectrum of CID of the ion of m/z 1067.7 of the novel compound 1.
  • FIG. 8 depicts a comparative study of fragmentation patterns for a) compound 1 and b) Permetina A.
  • FIG. 9 depicts the molecular formula of the lipopeptides a) BMY-28160 and b) Compound 2.
  • FIG. 10 depicts the spectrum of CID of the ion of m/z 1053.7 corresponding to compound 2.
  • FIG. 11 depicts a comparative study of fragmentation patterns for the lipopeptides a) BMY-28160 and b) compound 2.
  • the invention provides new agents with antimicrobial and growth promoter activity of organisms from the identification and isolation of these new agents of Paenibacillus .
  • the identification of these agents led to obtaining the extract of the fermentation broth and the preparation of peptides with antimicrobial activity and growth promoter of animals and plants.
  • the importance of this preparation lies in the fact that it permits the use of said extract and peptides, among others, to control bacteria and fungi that cause loss in raising of economically important animals (e.g., chickens and pigs).
  • said extract and peptides also act as growth promoters of plants and as inhibitors of plant infection by phytopathogens.
  • the invention is based on the process of obtaining, isolating and identifying new lipopeptide found in bacterial isolate extracts. These new bacterial compounds are capable of producing antimicrobial activity against numerous bacteria and fungi which cause veterinary infections, these strains already being resistant to the current antibiotics. Specifically, this invention provides, in one of its embodiments, the use of supernatant and/or extract of the culture comprising new lipopeptide found in bacterial isolate extracts to control veterinary infections and promote the growth of animals.
  • the separation process provided moieties which were analyzed, and at least two of the lipopeptides responsible for the antimicrobial activity were identified. This identification was performed by sequencing, and the results of this analysis demonstrated that there is no other sequence similar to the ones of the present invention in the databases of proteins and peptides, indicating that new lipopeptides with antimicrobial activity were isolated.
  • the present invention relates in a first embodiment to the process of obtaining a new bacterial extract having at least one biological activity among antimicrobial activity with respect to microorganisms that cause disease or damage in animals and plants and activity growth promoter of said animals and plants, said new bacterial extract being characterized in that it comprises at least one of the new compounds described below:
  • compound and “lipoprotein” are used interchangeably in the present invention to refer to the new chemical elements found in the extract from Paenibacillus , preferably in the extract from Paenibacillus elgii , more preferably in the extract from Paenibacillus elgii ourofinensis.
  • bacterial extract is intended to mean, in this description, the extract obtained from processing Paenibacillus , preferably from fermented Paenibacillus .
  • processing of fermented Paenibacillus for the extraction is carried out by methods known in the art such as, for example, liquid-liquid extraction using an organic solvent such as, but not limited to, n-butanol, or by extraction with ion-exchange cartridge.
  • the present invention also relates to specific peptides having compounds 1 and/or 2 described below:
  • lipopeptides of the present invention may be produced by known techniques and obtained in a substantially pure form.
  • lipopeptides can be synthesized manually or in an automated synthesizer, or they may be isolated from the fermentation broth of bacteria Paenibacillus.
  • the present invention also relates to drug compositions for the treatment and prophylaxis of animals from animals intended for human consumption, said compositions comprising: (i) a therapeutically effective amount of at least one of the compounds of the present invention; and (ii) a pharmaceutically acceptable carrier or excipient; and (iii) optionally, a therapeutic adjuvant.
  • the lipopeptides of the invention have antimicrobial activity and/or activity growth promoter of said animals.
  • the invention also relates to a drug composition for the treatment and prophylaxis of animals intended for human consumption, said compositions comprising: (i) a therapeutically effective amount of the culture extract of Paenibacillus having at least one of the compounds of the present invention; (ii) a pharmaceutically acceptable carrier or excipient; (iii) optionally, a therapeutic adjuvant.
  • Said extract can be in the liquid form, corresponding to the liquid phase (supernatant) separated from the fermentation broth, or it may be in the dry state after drying, for example, by lyophilization of said liquid phase.
  • compositions of the invention contain as active ingredient at least one of the lipopeptides of the present invention, or mixtures thereof, in combination with a pharmaceutically acceptable carrier or diluent, and optionally one or more therapeutic adjuvants. Therefore, the active ingredients according to the invention can be administered individually or together in any conventional dosage/veterinary form of oral or parenteral administration.
  • the composition of the invention may be in the form of a solution, suspension, tablet, pill, capsule, powder, and the solid forms can be of quick release, controlled release or delayed release, or any combination of these types, and said forms may be added to the water or feed of animals.
  • the tablet form contains various excipients such as sodium citrate, calcium carbonate, calcium phosphate and the like, along with disintegrants such as starch or complex silicates. It is also common the use of binding agents in this dosage form such as polyvinylpyrrolidone, sucrose, gelatin and acacia, and additionally lubricating agents such as magnesium stearate, sodium lauryl sulfate and acacia.
  • solid dosage/veterinary forms include powders which can be either water dispersible or they may be enclosed in gelatin capsules as hard-type capsules or soft-type capsules.
  • the excipient includes lactose or polyethylene glycols of varying molecular weights.
  • sweeteners In the case of liquid dosage forms for oral administration, sweeteners, flavoring agents, dyes, emulsifying agents or suspending enhancers and diluents may be used in the excipient, such as water, ethanol, propylene glycol, glycerin and combinations thereof.
  • compositions containing the active ingredients of the invention are usually prepared following conventional methods, and are administered in the appropriate dosage/veterinary form.
  • the oral solid dosage/veterinary forms may contain, along with the active ingredient, diluents, lubricants, binders, disintegrating agents and others.
  • diluents that may be used in the pharmaceutical/veterinary compositions of the invention are: lactose, dextrose, saccharose, cellulose, corn starch or potato starch.
  • lubricants that may be used in the pharmaceutical/veterinary compositions of the invention are: silica, talc, stearic acid, magnesium or calcium stearate and/or polyethylene glycols.
  • binding agents that may be used in the pharmaceutical/veterinary compositions of the invention are: starches, arabic gum, gelatin, methylcellulose, carboxymethylcellulose or polyvinyl pyrrolidone.
  • disaggregating agents that may be used in the pharmaceutical/veterinary compositions of the invention are: starch, alginic acid, starch or sodium alginates or glycolates; effervescent mixtures; dyes; sweeteners.
  • the pharmaceutical/veterinary compositions of the invention can use wetting agents such as lectin, polysorbates, laurylsulphates, and in general, pharmacologically inactive and non-toxic substances commonly used in pharmaceutical/veterinary formulations.
  • the preparation of said pharmaceutical/veterinary compositions of the invention can be carried out in a known manner, for example by means of mixing, granulating, pressing into tablets, sugar-coating, or film-coating processes.
  • the liquid dispersions for oral administration may be e.g. syrups, emulsions and suspensions.
  • the syrups may contain one or more carrier agents, for example, saccharose or saccharose with glycerine and/or mannitol and/or sorbitol.
  • the suspensions and the emulsions may contain as carrier, for example, a natural gum, agar, sodium alginate, pectin, methylcellulose, carboxymethylcellulose or polyvinyl alcohol.
  • sterile, pharmaceutically acceptable oils, and propylene glycol may also be employed, as well as sterile aqueous solutions.
  • the drug compositions of the present invention may also contain one or more therapeutic adjuvants.
  • therapeutic adjuvants are: phosphatide-polysaccharide conjugate as described in U.S. Pat. No. 5,785,975; Veterinary emulsion-based adjuvants, e.g.
  • Emulsigen®, Carbigen®, Polygen® available from the company MPV Technologies
  • adjuvants such as the acrylic polymer and the dimethyl dioctadecyl ammonium bromide, disclosed in US2009/0017067
  • sub-micron oil-in-water squalene emulsion, polyoxyethylene, sorbitan monooleate and sorbitan trioleate known by the brand name MF59TM, available from the company Novartis, and other examples may also be mentioned.
  • the invention also relates to a composition for the prophylaxis and treatment of plants comprising: (i) a therapeutically effective amount of at least one of the lipopeptides of the present invention; (ii) an agriculturally acceptable carrier or substrate; and (iii) optionally, at least one additive.
  • said composition for the treatment and prophylaxis of plants comprises: (i) an agriculturally effective amount of the culture extract of Paenibacillus comprising the lipopeptide of the present invention; (ii) an agriculturally acceptable carrier or substrate; and (iii) optionally, at least one additive.
  • the formulation of the invention may be in liquid or solid form, for example in the form of a wettable powder. Both formulations, dry or liquid, shall be packed in containers and in conditions that preserve the integrity of the active ingredients. Liquid formulations have lower shelf life, but the dry formulations (e.g., wettable powder) require less stringent conditions, such as storage in a cool place in the absence of light and moisture, and the product may be stored from one crop to another, since packed in freezer or refrigerator.
  • compositions of the invention generally contain an amount of active ingredient effective to control microorganisms harmful to plants and/or promote plant growth, said active ingredient comprising the lipopeptides of the present invention described below:
  • the formulations of the invention will typically contain effective amounts of the active ingredient, one or more diluents, one or more surfactants and other appropriate additives to obtain the desired product characteristics. Furthermore, it should be clear that the active ingredient used in the present invention can also be used alone in special applications where a high concentration of the composition of the invention is required.
  • compositions of the invention can be added to the compositions of the invention such as additives to reduce foaming, clumps, corrosion, unwanted microbial growth, and other similar agents.
  • Another essential feature of the formulation of the present invention is the need for ensuring that all ingredients of the composition are mutually compatible and do not contribute to loss of antimicrobial and/or growth promoter activity characteristic of the active ingredient of the invention.
  • compositions of the present invention can also be mixed with other agricultural chemicals, fertilizers, soil conditioners, stabilizers, or with one or more insecticides, fungicides, acaricides, or other biologically active compounds to form a multicomponent formulation.
  • other protection products in agriculture as the active ingredient of the formulation of the present invention that may be mixed are insecticide-type sodium channel agonist (e.g., pyrethroid), sodium channel blocking agents (for example, pyrazolines), acetylcholinesterase inhibitors (e.g., organophosphates and carbamates), nicotinic acetylcholine binding agents, gabaergic binders, agonists or antagonists of octapine (e.g., formamidine) insecticides from the pyrrole group and others.
  • insecticide-type sodium channel agonist e.g., pyrethroid
  • sodium channel blocking agents for example, pyrazolines
  • acetylcholinesterase inhibitors e.g
  • the organic extract obtained by liquid-liquid extraction of Paenibacillus elgii fermented in n-butanol shows a mixture of 5 lipopeptides belonging to the class of Permetinas.
  • compounds of m/z 1067.7 and 1053.7 are unpublished.
  • the signal of m/z 1101.7 was assigned to the presence of permetina A
  • the signal of m/z 1087.7 was assigned to the presence of compound BMY-28160
  • the signal of m/z 1073.7 was assigned to the compound Pelgipeptin A.
  • These compounds were characterized by ultra resolution mass spectrometry using a spectrometer FT-ICR-MS and collision-induced dissociation experiments (CID). These two experiments confirm the proposed structure for all lipopeptides present in the organic extract produced by Paenibacillus elgii , as detailed below.
  • the organic extract obtained by liquid-liquid extraction of fermented Paenibacillus elgii in n-butanol was analyzed by ultrasonic resolution mass spectrometry. The spectrum obtained is shown in FIG. 1 .
  • Permetinas are lipopeptide containing 9 amino acids linked to a lipid chain of a 6-carbon ⁇ -hydroxy acid.
  • the signal of m/z 1101.7024 was assigned to the presence of Permetina A ( FIG. 2 ).
  • the signal of m/z 1101.7 was subjected to sequence mass spectrometry experiments (MS/MS) for fragmentation and structural characterization studies.
  • the spectrum of collision-induced fragmentation (ICD) is shown in FIG. 3 .
  • the signal of m/z 1087.6868 which was attributed to the presence of the lipopeptide BMY-28160, is a lipopeptide analogue of Permetina A.
  • the amino acid at position 2 is Valine (Val), different from Permetina A, where the amino acid in this second position is a Leucine/Isoleucine (Leu/Ile) as shown in FIG. 5 .
  • the signal of m/z 1067.7193 was attributed to the presence of the lipopeptide analogue of Permetina A ( FIG. 6 ).
  • the amino acid sequence of compound 1 was characterized as an analog of Permetina A in which the amino acid phenylalanine (Phe) in position 4 of Permetina A was replaced by the amino acid leucine/isoleucine (Leu/Ile) in FIG. 6
  • FIG. 8 A comparative study of fragmentation patterns for Permetina A and compound 1 is presented in FIG. 8 .
  • the signal of m/z 1053.7 observed in the mass spectrum of the crude extract ( FIG. 1 ) was assigned to a second novel compound.
  • This compound was characterized as being a lipopeptide analogue to lipopeptide BMY-28160.
  • the structural difference between the two compounds is that for the lipopeptide BMY-28160 the amino acid at position 4 is a Phenylalanine (Phe) and for the novel compound the amino acid at position 4 is a leucine/isoleucine (Leu/Ile) as shown in FIG. 9 .
  • the signal of m/z 1053.7 was subjected to CID experiments with the aim of obtaining information about the amino acid sequencing of this new compound.
  • the fragmentation spectrum obtained is shown in FIG. 10 .

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Polymers & Plastics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Animal Husbandry (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Birds (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Dentistry (AREA)
  • Pest Control & Pesticides (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Agronomy & Crop Science (AREA)
  • Environmental Sciences (AREA)
  • Physiology (AREA)
US14/111,707 2011-04-12 2011-04-12 Peptides with antimicrobial activity, drug compositions for the treatment and prophylaxis of animals, compositions for the treatment and prophylaxis of plants, uses of said peptides, and uses of paenibacillus elgil ourofinensis extract Abandoned US20140113817A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/BR2011/000104 WO2012139179A1 (pt) 2011-04-12 2011-04-12 Peptídeos com atividade antimicrobiana, composições medicamentosas para o tratamento e profilaxia de animais, composições para o tratamento e profilaxia de plantas, usos dos ditos peptídeos, e, usos do extrato de paenibacillus elgii ourofinensis

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/BR2011/000104 A-371-Of-International WO2012139179A1 (pt) 2011-04-12 2011-04-12 Peptídeos com atividade antimicrobiana, composições medicamentosas para o tratamento e profilaxia de animais, composições para o tratamento e profilaxia de plantas, usos dos ditos peptídeos, e, usos do extrato de paenibacillus elgii ourofinensis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/686,417 Continuation-In-Part US9534019B2 (en) 2011-04-12 2015-04-14 Peptides with antimicrobial activity, drug compositions for the treatment and prophylaxis of animals, compositions for the treatment and prophylaxis of plants, uses of said peptides, and uses of Paenibacillus elgii ourofinensis extract

Publications (1)

Publication Number Publication Date
US20140113817A1 true US20140113817A1 (en) 2014-04-24

Family

ID=47008719

Family Applications (2)

Application Number Title Priority Date Filing Date
US14/111,707 Abandoned US20140113817A1 (en) 2011-04-12 2011-04-12 Peptides with antimicrobial activity, drug compositions for the treatment and prophylaxis of animals, compositions for the treatment and prophylaxis of plants, uses of said peptides, and uses of paenibacillus elgil ourofinensis extract
US14/686,417 Expired - Fee Related US9534019B2 (en) 2011-04-12 2015-04-14 Peptides with antimicrobial activity, drug compositions for the treatment and prophylaxis of animals, compositions for the treatment and prophylaxis of plants, uses of said peptides, and uses of Paenibacillus elgii ourofinensis extract

Family Applications After (1)

Application Number Title Priority Date Filing Date
US14/686,417 Expired - Fee Related US9534019B2 (en) 2011-04-12 2015-04-14 Peptides with antimicrobial activity, drug compositions for the treatment and prophylaxis of animals, compositions for the treatment and prophylaxis of plants, uses of said peptides, and uses of Paenibacillus elgii ourofinensis extract

Country Status (11)

Country Link
US (2) US20140113817A1 (de)
EP (1) EP2708551A4 (de)
JP (1) JP2014513080A (de)
KR (1) KR20140058423A (de)
CN (1) CN103649107A (de)
AU (1) AU2011365688C1 (de)
CO (1) CO6940372A2 (de)
MX (1) MX2013012045A (de)
NZ (1) NZ616686A (de)
RU (1) RU2013150203A (de)
WO (1) WO2012139179A1 (de)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107995925A (zh) * 2015-03-26 2018-05-04 拜耳作物科学有限合伙公司 新型类芽孢杆菌属菌株、抗真菌化合物以及它们的使用方法
CN110495530A (zh) * 2019-09-05 2019-11-26 中山大学 一种乌鳢幼鱼期浮性饲料及其制备方法

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101723012B1 (ko) 2016-04-29 2017-04-04 인하대학교 산학협력단 셀룰로오스 나노섬유를 포함하는 미세조류 응집제 및 이를 이용한 미세조류 회수 및 지질 함량 증대 방법
KR101935816B1 (ko) * 2016-08-25 2019-04-03 전남대학교산학협력단 페니바실러스 엘기로부터 추출한 신규 추출물 및 이의 용도
BR102017018881A2 (pt) * 2017-09-01 2019-03-19 União Brasiliense De Educação E Cultura - Ubec Meio de cultura mmp para produção de lipopeptideos antimicrobianos a partir do cultivo de bactérias, processo para produção de lipopeptideos antimicrobianos e uso do mesmo
CA3110143A1 (en) 2018-08-28 2020-03-05 Ultupharma Ab Peptide compounds
CN113354718B (zh) * 2021-06-21 2023-06-02 重庆市畜牧科学院 一种哌尼生素前体、表达盒及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5828869B2 (ja) * 1978-04-07 1983-06-18 味の素株式会社 抗生物質パ−メチンａ
JPS5696669A (en) * 1979-12-28 1981-08-04 Ajinomoto Co Inc Feed for cattle
US5785975A (en) 1995-06-26 1998-07-28 Research Triangle Pharmaceuticals Adjuvant compositions and vaccine formulations comprising same
CA2575769C (en) * 2004-08-09 2014-09-30 Shinichiro Kochi Novel strains belonging to the genus paenibacillus and method of controlling plant disease by using these strains or culture thereof
CL2008001806A1 (es) 2007-06-20 2008-09-05 Wyeth Corp Composicion de vacuna en emulsion agua en aceite que comprende un antigeno y un adyuvante en la fase acuosa; y metodo de elaboracion.
KR100954297B1 (ko) 2007-10-05 2010-04-20 김달수 표면 미생물의 밀도증진 조성물과 그 용도
BRPI0908664A2 (pt) * 2009-11-17 2012-02-22 Uniao Brasiliense De Educacao E Cultura Ubec peptìdeos com atividade antimicrobiana, composições medicamentosas para o tratamento e profilaxia de animais, composições para o tratamento e profilaxia de plantas, usos de ditos peptìdeos e usos do extrato de paenibacillus elgii ourofinensis com atividade antimicrobiana

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107995925A (zh) * 2015-03-26 2018-05-04 拜耳作物科学有限合伙公司 新型类芽孢杆菌属菌株、抗真菌化合物以及它们的使用方法
CN110495530A (zh) * 2019-09-05 2019-11-26 中山大学 一种乌鳢幼鱼期浮性饲料及其制备方法

Also Published As

Publication number Publication date
EP2708551A4 (de) 2014-11-12
AU2011365688C1 (en) 2016-01-07
AU2011365688A8 (en) 2013-11-14
RU2013150203A (ru) 2015-05-20
KR20140058423A (ko) 2014-05-14
EP2708551A1 (de) 2014-03-19
AU2011365688B2 (en) 2015-08-20
CO6940372A2 (es) 2014-05-09
MX2013012045A (es) 2014-05-27
CN103649107A (zh) 2014-03-19
US9534019B2 (en) 2017-01-03
AU2011365688A1 (en) 2013-11-07
JP2014513080A (ja) 2014-05-29
US20150218226A1 (en) 2015-08-06
WO2012139179A1 (pt) 2012-10-18
NZ616686A (en) 2015-05-29

Similar Documents

Publication Publication Date Title
US20140113817A1 (en) Peptides with antimicrobial activity, drug compositions for the treatment and prophylaxis of animals, compositions for the treatment and prophylaxis of plants, uses of said peptides, and uses of paenibacillus elgil ourofinensis extract
AU2015373978B2 (en) Seed endophytes across cultivars and species, associated compositions, and methods of use thereof
Liu et al. Development and applications of destruxins: A review
US11325955B2 (en) Stabilized anti-microbial peptides for the treatment of antibiotic-resistant bacterial infections
KR102145634B1 (ko) 사이클릭 디펩타이드 및 dl-3-페닐락틱산을 포함하는 항균, 항진균 및 항바이러스 조성물
KR20180002710A (ko) 항균 요법
Kumar et al. Purification of an antifungal compound, cyclo (l-Pro-d-Leu) for cereals produced by Bacillus cereus subsp. thuringiensis associated with entomopathogenic nematode
Janiszewska et al. Novel dendrimeric lipopeptides with antifungal activity
Menegatti et al. Paenibacillus polymyxa associated with the stingless bee Melipona scutellaris produces antimicrobial compounds against entomopathogens
Wang et al. Study on the biocontrol potential of antifungal peptides produced by Bacillus velezensis against Fusarium solani that infects the passion fruit Passiflora edulis
US9139616B2 (en) Isolation, identification, and uses of antifungal compounds
Digra et al. An insight into endophytic antimicrobial compounds: An updated analysis
Tang et al. Efficient preparation of sophorolipids and functionalization with amino acids to furnish potent preservatives
EP2721054A1 (de) Modifizierte antibiotische peptide mit variabler systemischer freisetzung
US7235262B2 (en) Use of bioactive fraction from cow urine distillate (‘Go-mutra’) as a bio-enhancer of anti-infective, anti-cancer agents and nutrients
CN106674331B (zh) 抗菌脂肽bacaucin及其制备方法与应用
CN117164665A (zh) 一种人鼻液α-2-巨球蛋白抗菌肽A2M3及其应用
WO2013096697A2 (en) Isolation, identification, and used of antifungal compounds
WO2007120253A2 (en) Endophytic streptomycetes, compounds derived therefrom, and methods of their use
KR100915855B1 (ko) 식물병원성 세균에 대한 항미생물 펩티드 ｋｃｍ１２
Chung et al. Antifungal and antioxidant peptides from oil palm mesocarps
Majumdar et al. A new antifungal antibiotic from Bacillus sp. KM5 isolated from rice rhizospheric soil
Singh et al. Studies on some phytoextracts for their antifungal activities against Microsporum canis
Das Slafractonia Leguminicola Toxin Transport, Temporal Expression and Secretion
US10131698B2 (en) Synthetic antimicrobial peptides

Legal Events

Date Code Title Description
AS Assignment

Owner name: UNIAO BRASILIENSE DE EDUCACAO E CULTURA - UBEC, BR

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HENRIQUE, CARLOS HENRIQUE;DE ARAUJO, JANAINA FERNANDEZ;DE CASTRO, ALINNE PEREIRA;AND OTHERS;SIGNING DATES FROM 20140703 TO 20140716;REEL/FRAME:033592/0667

Owner name: OURO FINO PARTICIPACOES E EMPREENDIMENTOS S/A, BRA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HENRIQUE, CARLOS HENRIQUE;DE ARAUJO, JANAINA FERNANDEZ;DE CASTRO, ALINNE PEREIRA;AND OTHERS;SIGNING DATES FROM 20140703 TO 20140716;REEL/FRAME:033592/0667

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION